Compare IHT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | TNXP |
|---|---|---|
| Founded | 1971 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 199.7M |
| IPO Year | 1995 | 2008 |
| Metric | IHT | TNXP |
|---|---|---|
| Price | $1.34 | $11.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.9K | ★ 419.2K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | $7,600,000.00 | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.33 | ★ 29.85 |
| 52 Week Low | $0.95 | $9.40 |
| 52 Week High | $4.24 | $29.19 |
| Indicator | IHT | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 44.02 |
| Support Level | $1.23 | $11.98 |
| Resistance Level | $1.51 | $13.18 |
| Average True Range (ATR) | 0.10 | 0.68 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 37.18 | 1.80 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.